Eikon Therapeutics (EIKN) investor relations material

Industry trends and macro environment

• China-originated innovation is increasing global competition and raising the quality of R&D outputs, with significant government investment driving progress.

• AI is integrated across business functions, primarily aiding data analysis and routine tasks, but is not central to strategic decision-making.

• Evolving commercial factors such as Most-Favored-Nation policies, IRA, and tariffs are more concerning than regulatory changes, especially regarding clinical trial logistics.

Clinical pipeline and data highlights

• EIK-1001, a TLR7/8 dual agonist, shows strong efficacy and safety in non-small cell lung cancer and melanoma, with mature data to be presented at ESMO.

• Registration-enabling studies for EIK-1001 are ongoing in both lung cancer (TeLuRide-008) and melanoma (TeLuRide-006), with interim analyses guiding dose selection and study progression.

• Melanoma study completion is event-driven, with overall survival data expected in the first half of 2029.

PARP1 selective inhibitor franchise

• EIK-1003 and EIK-1004 are highly selective PARP1 inhibitors with improved safety profiles, enabling combination with full-dose chemotherapy and potential use in brain metastases.

• Clinical data show reduced myelosuppression and allow for new treatment settings beyond maintenance, with updates forthcoming at ESMO.